PPTA Twitter

PlasmaProteins “Despite advances in tech that allow for production of certain plasma proteins from animal cells, human #plasma remains an important (and sometimes the only) reliable source of lifesaving therapeutic products for individual with #plasmaprotein deficiencies.” @BatesWhiteEcon
3 days ago.
PlasmaProteins Safety is our industry’s highest priority. Member companies adhere to strict regulatory & voluntary standards to ensure the safety of #plasmaprotein therapies. Learn more about our standards: bit.ly/2GxB64v
3 days ago.

Plasma Protein Therapeutics Association

The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by small patient populations worldwide to treat a variety of rare diseases and serious medical conditions.

Erica XLA

PPTA works globally to:

    • Advocate for access to and affordability of therapies for patients
    • Engage in constructive dialogue with regulatory agencies
    • Collaborate with patient advocacy organizations

PPTA also administers standards and programs that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100